Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

Kizzmekia S Corbett, Martha C Nason, Britta Flach, Matthew Gagne, Sarah O'Connell, Timothy S Johnston, Shruti N Shah, Venkata Viswanadh Edara, Katharine Floyd, Lilin Lai, Charlene McDanal, Joseph R Francica, Barbara Flynn, Kai Wu, Angela Choi, Matthew Koch, Olubukola M Abiona, Anne P Werner, Juan I Moliva, Shayne F Andrew, Mitzi M Donaldson, Jonathan Fintzi, Dillon R Flebbe, Evan Lamb, Amy T Noe, Saule T Nurmukhambetova, Samantha J Provost, Anthony Cook, Alan Dodson, Andrew Faudree, Jack Greenhouse, Swagata Kar, Laurent Pessaint, Maciel Porto, Katelyn Steingrebe, Daniel Valentin, Serge Zouantcha, Kevin W Bock, Mahnaz Minai, Bianca M Nagata, Renee van de Wetering, Seyhan Boyoglu-Barnum, Kwanyee Leung, Wei Shi, Eun Sung Yang, Yi Zhang, John-Paul M Todd, Lingshu Wang, Gabriela S Alvarado, Hanne Andersen, Kathryn E Foulds, Darin K Edwards, John R Mascola, Ian N Moore, Mark G Lewis, Andrea Carfi, David Montefiori, Mehul S Suthar, Adrian McDermott, Mario Roederer, Nancy J Sullivan, Daniel C Douek, Barney S Graham, Robert A Seder, Kizzmekia S Corbett, Martha C Nason, Britta Flach, Matthew Gagne, Sarah O'Connell, Timothy S Johnston, Shruti N Shah, Venkata Viswanadh Edara, Katharine Floyd, Lilin Lai, Charlene McDanal, Joseph R Francica, Barbara Flynn, Kai Wu, Angela Choi, Matthew Koch, Olubukola M Abiona, Anne P Werner, Juan I Moliva, Shayne F Andrew, Mitzi M Donaldson, Jonathan Fintzi, Dillon R Flebbe, Evan Lamb, Amy T Noe, Saule T Nurmukhambetova, Samantha J Provost, Anthony Cook, Alan Dodson, Andrew Faudree, Jack Greenhouse, Swagata Kar, Laurent Pessaint, Maciel Porto, Katelyn Steingrebe, Daniel Valentin, Serge Zouantcha, Kevin W Bock, Mahnaz Minai, Bianca M Nagata, Renee van de Wetering, Seyhan Boyoglu-Barnum, Kwanyee Leung, Wei Shi, Eun Sung Yang, Yi Zhang, John-Paul M Todd, Lingshu Wang, Gabriela S Alvarado, Hanne Andersen, Kathryn E Foulds, Darin K Edwards, John R Mascola, Ian N Moore, Mark G Lewis, Andrea Carfi, David Montefiori, Mehul S Suthar, Adrian McDermott, Mario Roederer, Nancy J Sullivan, Daniel C Douek, Barney S Graham, Robert A Seder

Abstract

Immune correlates of protection can be used as surrogate endpoints for vaccine efficacy. Here, nonhuman primates (NHPs) received either no vaccine or doses ranging from 0.3 to 100 μg of the mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. mRNA-1273 vaccination elicited circulating and mucosal antibody responses in a dose-dependent manner. Viral replication was significantly reduced in bronchoalveolar lavages and nasal swabs after SARS-CoV-2 challenge in vaccinated animals and most strongly correlated with levels of anti–S antibody and neutralizing activity. Lower antibody levels were needed for reduction of viral replication in the lower airway than in the upper airway. Passive transfer of mRNA-1273–induced immunoglobulin G to naïve hamsters was sufficient to mediate protection. Thus, mRNA-1273 vaccine–induced humoral immune responses are a mechanistic correlate of protection against SARS-CoV-2 in NHPs.

Figures

Fig. 1.. Antibody responses following mRNA-1273 immunization.
Fig. 1.. Antibody responses following mRNA-1273 immunization.
(A to F) Rhesus macaques were immunized according to fig. S1 with PBS (gray) or mRNA-1273 (0.3 μg – green, 1 μg – purple, 3 μg – orange, 10 μg – blue, 30 μg – pink, or 100 μg – red). Sera collected 4 weeks post-boost, immediately before challenge, were assessed for SARS-CoV-2 S-specific (A) and RBD-specific (B) IgG by MULTI-ARRAY ELISA, inhibition of ACE2 binding to RBD (C), SARS-CoV-2 lentiviral-based pseudovirus neutralization (D), SARS-CoV-2 VSV-based pseudovirus neutralization (E), and SARS-CoV-2 EHC-83E focus reduction neutralization (F). (G to J) BAL (G and I) and nasal washes (H and J) collected 2 weeks post-boost were assessed for SARS-CoV-2 S-specific IgG (G to H) and IgA (I to J) by MULTI-ARRAY ELISA. Squares represent NHPs in previous experiments (S1A, VRC-20–857.1 and S1B, VRC-20–857.2) and circles represent individual NHPs in experiment S1C, VRC-20–857.4. Boxes and horizontal bars denote the IQR and medians, respectively. Whisker endpoints are equal to the maximum and minimum values. Dotted lines indicate assay limits of detection, where applicable. NT: not tested. All measures were significantly correlated with dose (P<0.0001), as determined by a test of Spearman’s correlation.
Fig. 2.. Correlations of humoral antibody analyses.
Fig. 2.. Correlations of humoral antibody analyses.
Rhesus macaques were immunized according to fig. S1C. Plots show correlations between SARS-CoV-2 S-specific IgG, RBD-specific IgG, ACE2 binding inhibition, lentiviral-based pseudovirus neutralization, VSV-based pseudovirus neutralization, and EHC-83E focus reduction neutralization at 4 weeks post-boost. Circles represent individual NHPs, where colors indicate the mRNA-1273 dose as defined in fig. S1C. Dotted lines indicate assay limits of detection. Black and gray lines indicate linear regression and 95% confidence interval, respectively. “r” represents Spearman’s correlation coefficients and “P” represents the corresponding P-values.
Fig. 3.. Efficacy of mRNA-1273 against upper…
Fig. 3.. Efficacy of mRNA-1273 against upper and lower respiratory viral replication.
Rhesus macaques were immunized and challenged as described in fig. S1C. BAL (A) and nasal swabs (NS) (B) were collected on days 2 (squares), 4 (triangles), and 7 (diamonds) post-challenge, and viral replication was assessed by detection of SARS-CoV-2 N-specific sgRNA. (A and B) Boxes and horizontal bars denote the IQR and medians, respectively. Whisker endpoints are equal to the maximum and minimum values. (C to E) Correlations shown between BAL and NS sgRNA at days 2 (C), 4 (D), and 7 (E) post-challenge are Spearman’s correlation coefficients (r) and corresponding P-values. Symbols represent individual NHP and may overlap, i.e,. n=6 animals plotted at assay limit (dotted line) for both BAL and NS in (E).
Fig. 4.. Antibody correlates of protection.
Fig. 4.. Antibody correlates of protection.
Rhesus macaques were immunized and challenged as described in fig. S1C. Plots show correlations between SARS-CoV-2 N-specific sgRNA in BAL (A to F) and NS (G to L) at day 2 post-challenge and pre-challenge (week 4 post-boost) SARS-CoV-2 S-specific IgG (A and G), RBD-specific IgG (B and H), ACE2 binding inhibition (C and I), SARS-CoV-2 lentiviral-based pseudovirus neutralization (D and J), SARS-CoV-2 VSV-based pseudovirus neutralization (E and K) and SARS-CoV-2 EHC-83E focus reduction neutralization (F and L). Gray shading for S-specific IgG represents the use of this assessment as primary predictor of protection outcome as stated in primary hypothesis. (M) Plot shows correlation between pre-challenge (week 4 post-boost) SARS-CoV-2 S-specific IgG with day 28 post-challenge SARS-CoV-2 N-specific IgG. Circles represent individual NHPs, where colors indicate the mRNA-1273 dose. Dotted lines indicate assay limits of detection. Black and gray lines indicate linear regression and 95% confidence interval, respectively. In (M), a red dotted horizontal line represents 6, the maximum of all pre-challenge values across all groups, and a red dotted vertical line represents a reciprocal S-specific IgG titer of 500, above which none of the animals had day 28 N Binding titers above 6. “r” represents Spearman’s correlation coefficients and “P” represents the corresponding P-values
Fig. 5.. Passive transfer of mRNA-1273 immune…
Fig. 5.. Passive transfer of mRNA-1273 immune NHP IgG into Syrian hamsters.
(A) Sera were pooled from all NHP that received 100 μg of mRNA-1273 in a primary vaccination series. (B) mRNA-1273 immune NHP IgG (2 μg, yellow or 10 μg, orange) or pre-immune NHP IgG (10 μg, gray) was passively transferred to Syrian hamsters (n=8/group) 24 hours prior to SARS-CoV-2 challenge. Twenty-three hours post-immunization, hamsters were bled to quantify circulating S-specific IgG (C) and SARS-CoV-2 pseudovirus-neutralizing antibodies (D). Following challenge, hamsters were monitored for weight loss (E). (C and D) Circles represent individual NHP. Bars and error bars represent GMT and geometric SD, respectively. Asterisks at the axis represent animals that did not receive adequate IgG via passive transfer and were thus excluded from weight loss analyses. (D) The dotted line indicates the neutralization assay limit of detection. (E) Circles and error bars represent means and SEM, respectively.

Source: PubMed

3
Prenumerera